{"filings":[{"id":4038277,"accession_number":"0001193125-26-458486","cik":1853921,"company_name":"Scribe Therapeutics, Inc.","ticker":"SCTX","form_type":"8-K","filed_at":"2026-11-12T21:20:14+00:00","items":["2.02","9.01"],"status":"ready","headline":"Scribe Therapeutics Q3 2026 net loss $9.9M ($0.68/sh); $174.2M cash funds operations into 1H 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.9M ($0.68 per basic and diluted share) vs $6.5M net loss in Q2 2026; R&D $8.3M, G&A $4.2M, collaboration revenue $1.6M.","Cash, equivalents and marketable securities $174.2M at Sept 30, 2026 vs $43.0M at June 30, after ~$140.2M net IPO/private placement proceeds; runway into 1H 2029.","STX-1150 Phase 1 in elevated LDL-C ongoing; safety, tolerability and LDL-C data from single ascending dose expected 1H 2027; NHP data showed >50% LDL-C cut at 0.75 mg/kg for two years.","Expanded Sanofi collaboration to include ELXR epigenetic silencing technology, adding to XE gene editing and extending Sanofi's target nomination period; no financial terms disclosed.","July 2026 IPO upsized and priced at high end; ~$155.5M gross proceeds including underwriters' option and concurrent Sanofi private placement at the IPO price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2631440,"accession_number":"0001193125-26-380184","cik":1853921,"company_name":"Scribe Therapeutics, Inc.","ticker":"SCTX","form_type":"8-K","filed_at":"2026-09-02T20:08:19+00:00","items":["2.02","9.01"],"status":"ready","headline":"Scribe Therapeutics Q2 2026 net loss $6.5M; cash $43M plus $140.6M IPO proceeds fund to H1 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $6.5M ($2.62/share) vs $9.9M ($4.08) YoY; collaboration revenue $1.9M vs $4.9M.","Cash & marketable securities $43.0M at 6/30/26; July IPO + Sanofi placement raised $155.5M gross, $140.6M net.","Initiated first-in-human Phase 1 of STX-1150 (PCSK9 epigenetic silencing); NHP data showed up to 68% LDL-C reduction.","Awarded ~$25.7M CIRM grants: $12.7M for STX-1200 (Lp(a)), $13.0M for STX-1400 (triglycerides).","R&D expenses fell to $8.8M from $13.9M; management expects run-rate funding into H1 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1888276,"accession_number":"0001193125-26-318263","cik":1853921,"company_name":"Scribe Therapeutics, Inc.","ticker":"SCTX","form_type":"8-K","filed_at":"2026-07-27T21:08:53+00:00","items":["5.03","9.01"],"status":"ready","headline":"Scribe Therapeutics adopts amended charter and bylaws upon closing of IPO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Amended and Restated Certificate of Incorporation and Bylaws effective July 27, 2026.","Amendments adopted in connection with closing of initial public offering (IPO).","IPO described in final prospectus dated July 23, 2026 (Registration Statement S-1).","Board and stockholders previously approved the amendments prior to IPO closing.","Charter and Bylaws filed as Exhibits 3.1 and 3.2 to this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}